Key Points AbbVie survived Humira’s patent cliff. Its new billion-dollar drugs are picking up the slack. 10 stocks we like better than AbbVie › AbbVie (NYSE: ABBV) , one of the world's largest pharmaceutical companies , has been a reliable long-term investment. It's raised its dividend annually for 53 consecutive years, making it a Dividend King that has increased its payout for at least 50 years in a row, and a dozen of its drugs generate more than $1 billion in annual revenue. But as the 10-year Treasury yield stays above 5% -- its highest level since 2007 -- is it still smart to buy and hold this dividend stock? Image source: Getty Images. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.